高级检索
    冯卫能, 邓秋梅. 厄洛替尼联合抗血管生成药物对比厄洛替尼单药一线治疗EGFR突变晚期非小细胞肺癌的疗效[J]. 循证医学, 2020, 20(1): 53-57. DOI: 10.12019/j.issn.1671-5144.2020.01.012
    引用本文: 冯卫能, 邓秋梅. 厄洛替尼联合抗血管生成药物对比厄洛替尼单药一线治疗EGFR突变晚期非小细胞肺癌的疗效[J]. 循证医学, 2020, 20(1): 53-57. DOI: 10.12019/j.issn.1671-5144.2020.01.012
    shu
    FENG Wei-neng, DENG Qiu-mei. The Efficacy of Erlotinib Combined with Anti-Angiogenesis Treatment in Comparison with Erlotinib Alone as First-Line Treatment of EGFR-Mutated Advanced Non-Small Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2020, 20(1): 53-57. DOI: 10.12019/j.issn.1671-5144.2020.01.012
    Citation: FENG Wei-neng, DENG Qiu-mei. The Efficacy of Erlotinib Combined with Anti-Angiogenesis Treatment in Comparison with Erlotinib Alone as First-Line Treatment of EGFR-Mutated Advanced Non-Small Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2020, 20(1): 53-57. DOI: 10.12019/j.issn.1671-5144.2020.01.012
    shu

    厄洛替尼联合抗血管生成药物对比厄洛替尼单药一线治疗EGFR突变晚期非小细胞肺癌的疗效

    The Efficacy of Erlotinib Combined with Anti-Angiogenesis Treatment in Comparison with Erlotinib Alone as First-Line Treatment of EGFR-Mutated Advanced Non-Small Cell Lung Cancer

      摘要
      • HTML全文
      • 参考文献(9)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回